Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 2
1969 2
1970 4
1971 12
1972 4
1973 3
1989 1
1991 1
1992 3
1994 4
1996 1
1997 1
1998 2
1999 1
2000 5
2001 3
2002 3
2003 1
2004 3
2005 3
2006 5
2007 4
2008 1
2011 4
2012 3
2013 4
2014 2
2015 5
2016 3
2017 5
2018 2
2019 5
2020 8
2021 7
2022 2
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Rizvi NA, et al. Among authors: robinet g. JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237. JAMA Oncol. 2020. PMID: 32271377 Free PMC article. Clinical Trial.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Rosell R, et al. Among authors: robinet g. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285168 Clinical Trial.
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Garcia Campelo R, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Fournier B, Dingemans AC, Dziadziuszko R. Remon J, et al. Among authors: robinet g. Ann Oncol. 2023 May;34(5):468-476. doi: 10.1016/j.annonc.2023.02.012. Epub 2023 Feb 28. Ann Oncol. 2023. PMID: 36863484 Clinical Trial.
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.
Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, Razaq M, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G; ATALANTE-1 study group. Besse B, et al. Among authors: robinet g. Ann Oncol. 2023 Oct;34(10):920-933. doi: 10.1016/j.annonc.2023.07.006. Epub 2023 Sep 11. Ann Oncol. 2023. PMID: 37704166 Free article. Clinical Trial.
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, Corre R, Guisier F, Hominal S, Le Garff G, Bylicki O, Locher C, Geier M, Chouaïd C, Robinet G; GFPC team. Vergnenegre A, et al. Among authors: robinet g. Lung Cancer. 2023 Apr;178:191-197. doi: 10.1016/j.lungcan.2023.02.020. Epub 2023 Feb 27. Lung Cancer. 2023. PMID: 36868180 Clinical Trial.
Targeted therapy for localized non-small-cell lung cancer: a review.
Paleiron N, Bylicki O, André M, Rivière E, Grassin F, Robinet G, Chouaïd C. Paleiron N, et al. Among authors: robinet g. Onco Targets Ther. 2016 Jul 5;9:4099-104. doi: 10.2147/OTT.S104938. eCollection 2016. Onco Targets Ther. 2016. PMID: 27462164 Free PMC article. Review.
[Systemic treatment of brain metastases from lung cancer].
Barlesi F, Spano JP, Cortot AB, Carpentier AF, Robinet G, Besse B. Barlesi F, et al. Among authors: robinet g. Cancer Radiother. 2015 Feb;19(1):43-7. doi: 10.1016/j.canrad.2014.12.001. Epub 2015 Feb 2. Cancer Radiother. 2015. PMID: 25656857 Review. French.
A 60-Year-Old Woman With Recurrent Hemoptysis.
Geier M, Picart G, Khatchatourian L, Samaison L, Robinet G, Couturaud F, Bizien N. Geier M, et al. Among authors: robinet g. Chest. 2020 Dec;158(6):e273-e277. doi: 10.1016/j.chest.2020.06.069. Chest. 2020. PMID: 33280768
[A rare paratesticular tumor].
Robinet G, Rioux-Leclercq N, Fardoun T, Mathieu R, Kammerer-Jacquet SF. Robinet G, et al. Ann Pathol. 2017 Apr;37(2):206-208. doi: 10.1016/j.annpat.2016.10.003. Ann Pathol. 2017. PMID: 28318773 French. No abstract available.
120 results